Alpha 2.0
Login Register
» Authors » J Tyler Martin

J Tyler Martin

Explore the profile of J Tyler Martin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 167
Followers 0
Related Specialty
Allergy & Immunology
Top 10 Co-Authors
William L Heyward
Robert S Janssen
Scott A Halperin
Joanne M Langley
Donna MacKinnon-Cameron
Marc Dionne
Bruce Smith
Shelly McNeil
Hamid Namini
Martin L Kabongo
Published In
Vaccine
Hum Vaccin Immunother
Affiliations
Soon will be listed here.
Recent Articles
1.
Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus
Janssen J, Heyward W, Martin J, Janssen R
Vaccine . 2015 Jan; 33(7):833-7. PMID: 25576215
Background: Many patients with chronic kidney disease (CKD) are hyporesponsive to currently licensed alum-adjuvanted hepatitis B vaccines, including Engerix-B(®) (HBsAg-Eng). Seroprotection rates (SPRs) are further reduced in CKD patients with...
2.
Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease
Janssen R, Mangoo-Karim R, Pergola P, Girndt M, Namini H, Rahman S, et al.
Vaccine . 2013 Jun; 31(46):5306-13. PMID: 23727422
Background: Hemodialysis patients are at increased risk of hepatitis B virus (HBV) infection and patients with chronic kidney disease (CKD) are commonly hyporesponsive to HBV vaccines. Current recommendations for CKD...
3.
Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age
Heyward W, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo M, et al.
Vaccine . 2013 Jun; 31(46):5300-5. PMID: 23727002
Background: The currently licensed hepatitis B vaccines have limitations including hyporesponsiveness in older adults, poor compliance, and the extended time for most persons to develop seroprotection (e.g. >6months). A vaccine...
4.
Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine
Halperin S, Ward B, Dionne M, Langley J, McNeil S, Smith B, et al.
Hum Vaccin Immunother . 2013 Apr; 9(7):1438-44. PMID: 23571179
An additional one to three doses of hepatitis B vaccine are recommended for nonresponders to an initial standard three-dose series. We compared the safety and immunogenicity of an investigational hepatitis...
5.
Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults
Halperin S, McNeil S, Langley J, Smith B, MacKinnon-Cameron D, McCall-Sani R, et al.
Vaccine . 2012 Jun; 30(36):5445-8. PMID: 22704926
Background: Previous studies have shown that two doses of an investigational hepatitis B vaccine consisting of hepatitis B surface antigen combined with an immunostimulatory phosphorothioate oligodeoxyribonucleotide adjuvant (HBV-ISS) given 8...
6.
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in...
Halperin S, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, et al.
Vaccine . 2012 Feb; 30(15):2556-63. PMID: 22326642
Background: The currently licensed aluminum-hydroxide-adjuvanted hepatitis B vaccines require three doses over a 6-month period to achieve high rates of protection in adults. We compared tolerability and immunogenicity of two...